The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Open accessAbstract
Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies (e.g., CAR-T cells) and cytokine administration. In the last decades, it is emerging that the chemokine system represents a potential target for immunotherapy. Chemokines, a large family of cytokines with chemotactic activity, and their cognate receptors are expressed by both cancer and stromal cells. Their altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. Here, we review first attempts to inhibit the chemokine system in cancer as a monotherapy or in combination with canonical or immuno-mediated therapies. We also provide recent findings about the role in cancer of atypical chemokine receptors that could become future targets for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer
Wang, J., Shiozawa, Y., Wang, J., Wang, Y., Jung, Y., Pienta, K. J., Mehra, R., Loberg, R., & Taichman, R. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707465200 · Cited by 457
RetractedMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 2×
“AMD3100 + anti-PD-L1 Pancreatic cancer (89) AMD3100 Recurrent GBM NCI2012-00149;”
BackgroundChemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,059
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,449
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R. K., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 807
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R. S., Pienta, K. J., & Wang, J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9256-x · Cited by 727
CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer
Smith, M. C. P., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., Piwnica-Worms, D., & Luker, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1844 · Cited by 715
Cancer-related inflammation: Common themes and therapeutic opportunities
Balkwill, F. R., & Mantovani, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.005 · Cited by 685
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7
Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., Gerard, C., & Lefkowitz, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912852107 · Cited by 600
Homeostatic chemokine receptors and organ-specific metastasis
Zlotnik, A., Burkhardt, A. M., & Homey, B. (2011) · Nature Reviews Immunology · doi:10.1038/nri3049 · Cited by 571
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Nervi, B., Ramirez, P., Rettig, M. P., Uy, G. L., Holt, M. S., Ritchey, J. K., Prior, J. L., Piwnica-Worms, D., Bridger, G., Ley, T. J., et al. (2009) · Blood · doi:10.1182/blood-2008-06-162123 · Cited by 491
Nywening, T. M., Belt, B. A., Cullinan, D. R., Panni, R. Z., Han, B. J., Sanford, D. E., Jacobs, R. C., Ye, J., Patel, A. A., Gillanders, W. E., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-313738 · Cited by 489
Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 485
Tuning inflammation and immunity by chemokine sequestration: decoys and more
Mantovani, A., Bonecchi, R., & Locati, M. (2006) · Nature Reviews Immunology · doi:10.1038/nri1964 · Cited by 481 · cited 1×
“Atypical chemokine receptors (ACKRs) are emerging as crucial regulatory components of the chemokine network in a wide range of homeostatic and pathological conditions (109, 110).”
BackgroundSelf-citationKryczek, I., Lange, A., Mottram, P., Alvarez, X., Cheng, P., Hogan, M., Moons, L., Wei, S., Zou, L., Machelon, V., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.465.65.2 · Cited by 421
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis
Darash-Yahana, M., Pikarsky, E., Abramovitch, R., Zeira, E., Pal, B., Karplus, R., Beider, K., Avniel, S., Kasem, S., Galun, E., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0935fje · Cited by 421
CXC chemokines in angiogenesis
Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A., & Keane, M. P. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.007 · Cited by 414
The chemokine system and cancer
Balkwill, F. R. (2012) · The Journal of Pathology · doi:10.1002/path.3029 · Cited by 412
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Uy, G. L., Rettig, M. P., Motabi, I. H., McFarland, K., Trinkaus, K. M., Hladnik, L. M., Kulkarni, S., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383406 · Cited by 400
The chemokine system in cancer biology and therapy
Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., & Bonecchi, R. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.007 · Cited by 393
Self-citationTumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388 · cited 2×
“Finally, in a prostate cancer model, CXCR2 inhibition by SB265610, decreased recruitment of myeloid cells and enhanced Docetaxel-induced senescence, limiting tumor growth (76).”
BackgroundNatural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
Harnessing the immune system to improve cancer therapy
Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.01 · Cited by 307
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Kalbasi, A., Komar, C., Tooker, G. M., Liu, M., Lee, J. W., Gladney, W. L., Ben-Josef, E., & Beatty, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0870 · Cited by 305
Chemokine receptor antagonists: overcoming developmental hurdles
Horuk, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2734 · Cited by 303
Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment
Scala, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0914 · Cited by 290
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
The β-Chemokine Receptor D6 Is Expressed by Lymphatic Endothelium and a Subset of Vascular Tumors
Nibbs, R. J. B., Kriehuber, E., Ponath, P. D., Parent, D., Qin, S., Campbell, J. D. M., Henderson, A., Kerjaschki, D., Maurer, D., Graham, G. J., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64035-7 · Cited by 268
Organ selectivity in metastasis: regulation by chemokines and their receptors
Ben-Baruch, A. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9097-3 · Cited by 264
CXC Chemokines in Cancer Angiogenesis and Metastases
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06003-3 · Cited by 263
Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 246
Righi, E., Kashiwagi, S., Yuan, J., Santosuosso, M., Leblanc, P., Ingraham, R., Forbes, B., Edelblute, B., Collette, B., Xing, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3143 · Cited by 245
Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy
Mishra, P., Banerjee, D., & Ben-Baruch, A. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310182 · Cited by 239
Schott, A. F., Goldstein, L. J., Cristofanilli, M., Ruffini, P. A., McCanna, S., Reuben, J. M., Perez, R. P., Kato, G., & Wicha, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2748 · Cited by 238
Oyajobi, B. O., Franchin, G., Williams, P. J., Pulkrabek, D., Gupta, A., Munoz, S., Grubbs, B., Zhao, M., Chen, D., Sherry, B., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3905 · Cited by 215
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer
Lin, L., Chen, Y.-S., Yao, Y.-D., Chen, J.-Q., Chen, J.-N., Huang, S.-Y., Zeng, Y.-J., Yao, H.-R., Zeng, S.-H., Fu, Y.-S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5325 · Cited by 198
Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis
Takanami, I. (2003) · International Journal of Cancer · doi:10.1002/ijc.11063 · Cited by 198
Kitamura, T., Fujishita, T., Loetscher, P., Revesz, L., Hashida, H., Kizaka-Kondoh, S., Aoki, M., & Taketo, M. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002372107 · Cited by 178
Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10
Murakami, T., Cardones, A. R., Finkelstein, S. E., Restifo, N. P., Klaunberg, B. A., Nestle, F. O., Castillo, S. S., Dennis, P. A., & Hwang, S. T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030593 · Cited by 168
Thiriot, A., Perdomo, C., Cheng, G., Novitzky-Basso, I., McArdle, S., Kishimoto, J. K., Barreiro, O., Mazo, I., Triboulet, R., Ley, K., et al. (2017) · BMC Biology · doi:10.1186/s12915-017-0381-7 · Cited by 167
Kim, S.-J., Shin, J.-Y., Lee, K.-D., Bae, Y.-K., Sung, K. W., Nam, S. J., & Chun, K.-H. (2012) · Breast Cancer Research · doi:10.1186/bcr3098 · Cited by 164
Vetrano, S., Borroni, E. M., Sarukhan, A., Savino, B., Bonecchi, R., Correale, C., Arena, V., Fantini, M. C., Roncalli, M. G., Malesci, A., et al. (2009) · Gut · doi:10.1136/gut.2009.183772 · Cited by 162
Self-citationMacropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Cullis, J., Siolas, D., Avanzi, A., Barui, S., Maitra, A., & Bar-Sagi, D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0125 · Cited by 162
Yao, W., Ba, Q., Li, X., Li, H., Zhang, S., Yuan, Y., Wang, F., Duan, X., Li, J., Zhang, W., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.07.014 · Cited by 157
Massara, M., Persico, P., Bonavita, O., Poeta, V. M., Locati, M., Simonelli, M., & Bonecchi, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01349 · Cited by 153
Self-citationVallet, S., Raje, N. S., Ishitsuka, K., Hideshima, T., Podar, K., Chhetri, S., Pozzi, S., Breitkreutz, I., Kiziltepe, T., Yasui, H., et al. (2007) · Blood · doi:10.1182/blood-2007-05-093294 · Cited by 152
Peng, S.-B., Zhang, X., Paul, D. C., Kays, L. M., Gough, W. H., Stewart, J. A., Uhlik, M. T., Chen, Q., Hui, Y., Zamek‐Gliszczynski, M. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0850 · Cited by 150
The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors
Nibbs, R. J. B., Gilchrist, D. S., King, V., Ferra, A., Forrow, S., Hunter, K. D., & Graham, G. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30068 · Cited by 149
Pernas, S., Martín, M., Kaufman, P. A., Gil-Martín, M., Pardo, P. G., López‐Tarruella, S., Manso, L., Ciruelos, E. M., Fidalgo, J. A. P., Hernándo, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30147-5 · Cited by 148
Wang, J., Ou, Z.-L., Hou, Y.-F., Luo, J.-M., Shen, Z.-Z., Ding, J., & Shao, Z.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209703 · Cited by 147
The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth
Shen, H., Schuster, R. M., Stringer, K. F., Waltz, S. E., & Lentsch, A. B. (2006) · The FASEB Journal · doi:10.1096/fj.05-4764com · Cited by 140
Hensbergen, P. J., Wijnands, P. G. J. T. B., Schreurs, M. W. J., Scheper, R. J., Willemze, R., & Tensen, C. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000165355.26795.27 · Cited by 139
Bonecchi, R., Locati, M., Galliera, E., Vulcano, M., Sironi, M., Fra, A., Gobbi, M., Vecchi, A., Sozzani, S., Haribabu, B., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4972 · Cited by 138
Self-citationPapillary Carcinoma of the Thyroid
Scarpino, S., Stoppacciaro, A., Ballerini, F., Marchesi, M., Prat, M., Stella, M. C., Sozzani, S., Allavena, P., Mantovani, A., & Ruco, L. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64951-6 · Cited by 135
CCR2 expression correlates with prostate cancer progression
Lü, Y., Cai, Z. Y., Xiao, G., Liu, Y., Keller, E. T., Yao, Z., & Zhang, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21220 · Cited by 131
Sharma, B., Nawandar, D. M., Nannuru, K. C., Varney, M. L., & Singh, R. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0529 · Cited by 130
CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer
Wu, Y.-C., Tang, S., Sun, G.-H., & SUN, K.-H. (2015) · Oncogene · doi:10.1038/onc.2015.274 · Cited by 122
Cho, B., Zeng, Z., Mu, H., Wang, Z., Konoplev, S. N., McQueen, T. J., Protopopova, M. N., Cortes, J. E., Marszalek, J. R., Peng, S., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628677 · Cited by 121
The potential to target CCL5/CCR5 in breast cancer
Velasco-Velázquez, M. A., Xolalpa, W., & Pestell, R. G. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.949238 · Cited by 115
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Galsky, M. D., Vogelzang, N. J., Conkling, P., Raddad, E., Polzer, J. P., Roberson, S., Stille, J. R., Saleh, M. N., & Thornton, D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2686 · Cited by 115
The Role of CC-Chemokines in the Regulation of Angiogenesis
Ridiandries, A., Tan, J. T. M., & Bursill, C. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111856 · Cited by 114
Roles for Innate Immunity in Combination Immunotherapies
Moynihan, K. D., & Irvine, D. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1340 · Cited by 114
Addison, C., Belperio, J. A., Burdick, M. D., & Strieter, R. M. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-28 · Cited by 109
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Berlato, C., Khan, M. N., Schioppa, T., Thompson, R. D., Maniati, E., Montfort, A., Jangani, M., Canosa, M., Kulbe, H., Hagemann, U. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci82976 · Cited by 108
Lepore, F., D’Alessandro, G., Antonangeli, F., Santoro, A., Esposito, V., Limatola, C., & Trettel, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02750 · Cited by 107
ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity
Massara, M., Bonavita, O., Savino, B., Caronni, N., Poeta, V. M., Sironi, M., Setten, E., Recordati, C., Crisafulli, L., Ficara, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03080-8 · Cited by 103
Self-citationYoung, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J. C., Kamarashev, J. A., Frederick, D. T., Cooper, Z. A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160855 · Cited by 100
Perera, L. P., Zhang, M., Nakagawa, M., Petrus, M. N., Maeda, M., Kadin, M. E., Waldmann, T. A., & Perera, P. (2017) · American Journal of Hematology · doi:10.1002/ajh.24794 · Cited by 99
Feng, L.-Y., Ou, Z.-L., Wu, F.-Y., Shen, Z., & Shao, Z. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2495 · Cited by 98
Comerford, I., Nibbs, R. J. B., Litchfield, W., Bunting, M. D., Harata‐Lee, Y., Haylock‐Jacobs, S., Forrow, S., Körner, H., & McColl, S. R. (2010) · Blood · doi:10.1182/blood-2010-01-264390 · Cited by 93
Hawila, E., Razon, H., Wildbaum, G., Blattner, C., Sapir, Y., Shaked, Y., Umansky, V., & Karin, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.104 · Cited by 93
Linehan, D. C., Noel, M. S., Hezel, A. F., Wang‐Gillam, A., Eskens, F. A. L. M., Sleijfer, S., Desar, I. M. E., Erdkamp, F., Wilmink, J. W., Diehl, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.92 · Cited by 93
CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells
Ieranò, C., Santagata, S., Napolitano, M., Guardia, F., Grimaldi, A., Antignani, E., Botti, G., Consales, C., Riccio, A., Nanayakkara, M., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.269 · Cited by 88
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Dairaghi, D. J., Oyajobi, B. O., Gupta, A., McCluskey, B., Miao, S., Powers, J. P., Seitz, L. C., Wang, Y., Zeng, Y., Zhang, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384784 · Cited by 86
CXCR7: A novel tumor endothelial marker in renal cell carcinoma
Maishi, N., Ohga, N., Hida, Y., Akiyama, K., Kitayama, K., Osawa, T., Onodera, Y., Shinohara, N., Nonomura, K., Shindoh, M., et al. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02792.x · Cited by 83
Atypical chemokine receptors in cancer: friends or foes?
Massara, M., Bonavita, O., Mantovani, A., Locati, M., & Bonecchi, R. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0915-431rr · Cited by 79
Self-citationLau, T., Chung, T. K. H., Cheung, T., Chan, L. K., Cheung, L. W., Yim, S. F., Siu, N. S. S., Lo, K. W., Yu, M. M. Y., Kulbe, H., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4258 · Cited by 78
Ling, X., Spaeth, E. L., Chen, Y., Shi, Y., Zhang, W., Schober, W. D., Hail, N., Konopleva, M. Y., & Andreeff, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058426 · Cited by 78
Yang, X. L., Liu, K. Y., Lin, F. J., Shi, H. M., & Ou, Z. L. (2017) · Oncology Reports · doi:10.3892/or.2017.5798 · Cited by 78
Myeloid cells in cancer-related inflammation
Caronni, N., Savino, B., & Bonecchi, R. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.10.001 · Cited by 74
Self-citationThe chemokine receptors ACKR2 and CCR2 reciprocally regulate lymphatic vessel density
Lee, K. M., Danuser, R., Stein, J. V., Graham, D., Nibbs, R. J. B., & Graham, G. J. (2014) · The EMBO Journal · doi:10.15252/embj.201488887 · Cited by 74
CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors
Santoni, M., Sergio Bracarda, A., Nabissi, M., Massari, F., Conti, A., Bria, E., Tortora, G., Santoni, G., & Cascinu, S. (2014) · BioMed Research International · doi:10.1155/2014/768758 · Cited by 73
Wang, J., Hu, W., Wang, K., Yu, J., Luo, B., Luo, G., Wang, W., Wang, H., Li, J., & Wen, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3371 · Cited by 73
Gravina, G. L., Mancini, A., Marampon, F., Colapietro, A., Monache, S. D., Sferra, R., Vitale, F., Richardson, P. J., Patient, L., Burbidge, S. A., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0377-8 · Cited by 71
CCR7 Mediates Inflammation-Associated Tumor Progression
Mburu, Y. K., Wang, J., Wood, M. A., Walker, W. H., & Ferris, R. L. (2006) · Immunologic Research · doi:10.1385/ir:36:1:61 · Cited by 70
Yao, M., Fang, W. B., Smart, C., Hu, Q., Huang, S., Alvarez, N. S., Fields, P. E., & Cheng, N. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0750 · Cited by 67
Beider, K., Ribakovsky, E., Abraham, M., Wald, H., Weiss, L., Rosenberg, E., Galun, E., Avigdor, A., Eizenberg, O., Peled, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3015 · Cited by 66
Salazar, N., Carlson, J. C., Huang, K., Zheng, Y., Oderup, C., Gross, J. L., Jang, A., Burke, T. M., Lewén, S., Scholz, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.030 · Cited by 64
Freitas, C., Desnoyer, A., Meuris, F., Bachelerie, F., Balabanian, K., & Machelon, V. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.04.006 · Cited by 61
Targeting the Immune System in Cancer
Chaudhuri, D., Suriano, R., Mittelman, A., & Tiwari, R. K. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109787315114 · Cited by 61
The Duffy Antigen Receptor for Chemokines DARC/ACKR1
Horuk, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00279 · Cited by 61
Devapatla, B. K., Sharma, A., & Woo, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139237 · Cited by 58
Micallef, I. N., Stiff, P. J., Nademanee, A. P., Maziarz, R. T., Horwitz, M. E., Stadtmauer, E. A., Kaufman, J. L., McCarty, J. M., Vargo, R. L., Cheverton, P., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.039 · Cited by 57
Yu, X., Zhao, R., Lin, S., Bai, X., Zhang, L., Yuan, S., & Sun, L. (2015) · Oncology Reports · doi:10.3892/or.2015.4520 · Cited by 54
CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma
Cho, S. W., Kim, Y. A., Sun, H. J., Kim, Y. A., Oh, B., Yi, K. H., Park, D. J., & Park, Y. J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0196 · Cited by 53
Pham, K., Luo, D., Siemann, D. W., Law, B. K., Reynolds, B. A., Hothi, P., Foltz, G., & Harrison, J. K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.005 · Cited by 51
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
Liu, S., Gu, Y., Pascual, B., Yan, Z., Hallin, M. E., Zhang, C., Fan, C., Wang, W., Lam, J. L., Spilker, M. E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003921 · Cited by 51
Liang, K., Liu, Y., Dun, E., JingBin, L., Yang, F., & Hu, K. (2018) · Medical Science Monitor · doi:10.12659/msm.906230 · Cited by 49
Fuji, S., & Shindo, T. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.09.13 · Cited by 47
Bodduluri, S. R., Mathis, S., Maturu, P., Krishnan, E., Satpathy, S. R., Chilton, P. M., Mitchell, T. C., Lira, S., Locati, M., Mantovani, A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0424 · Cited by 45
The Atypical Chemokine Receptor Ackr2 Constrains NK Cell Migratory Activity and Promotes Metastasis
Hansell, C. A. H., Fraser, A. R., Hayes, A. J., Pingen, M., Burt, C. L., Lee, K. M., Medina‐Ruiz, L., Brownlie, D., MacLeod, M. K. L., Burgoyne, P., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800131 · Cited by 45
Savino, B., Caronni, N., Anselmo, A., Pasqualini, F., Borroni, E. M., Basso, G., Celesti, G., Laghi, L., Tourlaki, A., Boneschi, V., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0202 · Cited by 44
Self-citationGagner, J., Sarfraz, Y., Ortenzi, V., Alotaibi, F. M., Chiriboga, L. A., Tayyib, A. T., Douglas, G. J., Chevalier, É., Romagnoli, B., Tuffin, G., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.020 · Cited by 43
Chemokines as effector and target molecules in vascular biology
Sozzani, S., Prete, A. D., Bonecchi, R., & Locati, M. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv150 · Cited by 41
Self-citationChemokine regulation of neutrophil function in tumors
Bonavita, O., Massara, M., & Bonecchi, R. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.03.012 · Cited by 40
Self-citationLi, B., Zeng, Y. C., Reeves, P. M., Ran, C., Liu, Q., Qu, X., Liang, Y., Liu, Z., Yuan, J., Leblanc, P. R., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0530 · Cited by 40
CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells
González-Martín, A., Mira, E., & Mañes, S. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17995 · Cited by 36
CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas
Khanna, P., Chung, C.-Y., Neves, R. I., Robertson, G. P., & Dong, C. (2013) · Oncogene · doi:10.1038/onc.2013.249 · Cited by 35
Correale, P., Rotundo, M. S., Botta, C., Vecchio, M. T. D., Tassone, P., & Tagliaferri, P. (2012) · OncoImmunology · doi:10.4161/onci.19404 · Cited by 29
Caronni, N., Savino, B., Recordati, C., Villa, A. M., Locati, M., & Bonecchi, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3338-9_8 · Cited by 28
Self-citationCCX-CKR Expression in Colorectal Cancer and Patient Survival
Zhu, Y., Tang, W., Liu, Y., Wang, G., Liang, Z., & Cui, L. (2014) · The International Journal of Biological Markers · doi:10.5301/jbm.5000057 · Cited by 25
Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy
Beziaud, L., Boullerot, L., Tran, T., Mansi, L., Joseph, E. L. M., Ravel, P., Johannes, L., Bayry, J., Tartour, É., & Adotévi, O. (2018) · International Journal of Cancer · doi:10.1002/ijc.31842 · Cited by 24
Harata‐Lee, Y., Turvey, M. E., Brazzatti, J. A., Whyte, C. E., Brown, M. P., Smyth, M. J., Comerford, I., & McColl, S. R. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.58 · Cited by 21
Jung, H., Bischof, A. G., Ebsworth, K., Ertl, L. S., Schall, T. J., & Charo, I. F. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p227 · Cited by 18
The chemokine scavenging receptor D6/ACKR2 is a target of miR-146a in thyroid cancer
Pacifico, F., Lepore, A., Mellone, S., Sanguigno, L., Federico, G., Greco, A., Brunetti, A., & Leonardi, A. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.141 · Cited by 10
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Self-citationCombination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Metadata
- Authors
- Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-03-06
- Volume
- 10
- Pages
- 379-379
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2918297277
- Cited by
- 583
- References
- 125
- FWCI
- 29.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.